| 2型糖尿病的治疗新药——阿必鲁肽 |
| |
| 引用本文： | 朱 超,邵 华,于 锋,贺煜星.2型糖尿病的治疗新药——阿必鲁肽[J].药学与临床研究,2014,22(6):532-535. |
| |
| 作者姓名： | 朱 超 邵 华 于 锋 贺煜星 |
| |
| 作者单位： | 1. 中国药科大学临床药学教研室,南京,210009
2. 东南大学附属中大医院临床药学室,南京,210009 |
| |
| 摘 要： | 阿必鲁肽是胰高血糖样肽-1（GLP-1）类似物，于2014年3月和4月分别被欧洲药品评价署（E_MEA）和美国食品与药物管理局（FDA）批准上市，用于成年人2型糖尿病的治疗。临床研究表明，阿必鲁肽作为单药或与其他药物联合治疗，仅需每周皮下注射1次即可有效降低血糖和控制体重，而低血糖发生风险低、胃肠道不良反应少且轻。本文从其作用机制、药效学、药动学、临床疗效及安全性等方面作一综述。
|
| 关 键 词： | 阿必鲁肽 GLP-1类似物 2型糖尿病 药效学 药动学 安全性 |
| 收稿时间： | 2014/7/8 0:00:00 |
| 修稿时间： | 2014/7/20 0:00:00 |
Albiglutide,a Novel Treatment for Type 2 Diabetes |
| |
| ZHU Chao,SHAO Hu,YU Feng and HE Yu-xing.Albiglutide,a Novel Treatment for Type 2 Diabetes[J].Pharmacertical and Clinical Research,2014,22(6):532-535. |
| |
| Authors: | ZHU Chao SHAO Hu YU Feng and HE Yu-xing |
| |
| Institution: | ZHU Chao,SHAO Hua,YU Feng,HE Yu-xing(1.Department of Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, Jinngsu, China; 2.Department of Clinical Pharmacnlogy, Zhongda Haspital of Southeast University, Nanjing 210009, Jiangsu, China) |
| |
| Abstract: | Albiglutide is one of the glucagon-like peptide （GLP-1） analogues, approved by the European Medicines Evalu_ation Agency （EMEA） and the United States Food and Drug Administration （FDA） in March and April 2014, respectively, for the treatment of adults with type 2 diabetes. Clinical studies have shown that albiglutide subcutaneous injected once a week can effectively reduce blood glucose and control weight with low risk of hypoglycaemia, slight gastrointestinal adverse reactions as monotherapy or in combination with other hypoglycemic drugs. This review summarizes its mechanism of action, pharmaco_dynamics, pharmacokinetics, clinical efficacy and safety, etc. |
| |
| Keywords: | Albiglutide GLP-1 analogues Type 2 diabetes Pharmacodynamics Pharmacokinetics Safety |
| 本文献已被 维普 万方数据 等数据库收录！ |
| 点击此处可从《药学与临床研究》浏览原始摘要信息 |
| 点击此处可从《药学与临床研究》下载免费的PDF全文 |
|
